From an outside perspective, it seems as though politicians are embattled in zero-sum-game but however bleak as it may seem, the effects of their decisions alter our life as we know it. The vocal political figures, ones we see on several news channels at once, bang their chests and make statements like, “this bill is necessary in order to secure the future of our nation,” or “we cannot let this pass because it will destroy our sovereignty on a level
As citizens, we have no barometer for which of these statements is backed by factual information.
The only notion we can guarantee knowledge of is how certain legislative decisions will directly affect our way of life, namely our right to life, liberty, and the pursuit of something more than we were given.
Perhaps the most important area of legislative discussion is that which is based around healthcare. You could be the most embittered, sarcastic, pedantic individual to walk this Earth, but if you can’t afford health insurance, perhaps you’ll turn the other cheek before time runs out.
Earlier this month, the Trump Administration officially recommended a round of major changes to how insurers and pharmacy benefits managers (PBMs) interact in terms of drug rebates for Medicare.
Alex Azar, the Secretary of Health and Human Services, proposed that we cut drug prices by rolling back the rebate system that rewards high list prices, or, in simpler terms, lessening the discrepancy between what PBMs pay for drugs versus what the patient pays at the counter.
Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond
According to Fortune, PBMs such as CVS and Express Scripts, negotiate prices with drug makers “behind-the-scenes” and consumers have little to no idea how much rebates on list prices are awarded to them — versus passed directly onto the middlemen themselves.
“We applaud the Administration for taking steps to reform the rebate system to lower patients’ out-of-pocket costs. Our current health care system results in patients often paying cost-sharing based on the list price, regardless of the discount their insurer receives. We need to ensure that the $150 billion in negotiated rebates and discounts are used to lower costs for patients at the pharmacy…”
–PhRMA statement
Though it would seem that the Trump Administration’s recent initiative for lowering drug costs is bipartisan in nature, members of the Democratic leadership remain largely unconvinced. When Democrats were campaigning in 2018 to retake the house majority, they swore to voters that, if they succeeded, they would do everything in their collective powers to beat back President Trump’s disavowal of the Affordable Care Act.
As we all know, the Democratic “blue wave” swept across the House floor, and now the left controls the majority. Later this week, the House Committee On Energy and Commerce will hold a legislative hearing during the course of which House Democrats will lobby to rescind the Section 1332 guidance of the ACA. Since its promulgation in October 2018, Section 1332 has made it difficult for Americans to get insurance coverage because of how unclear language in the provision is regarding pre-existing conditions.
At a time where the fate of our nation’s healthcare is largely uncertain, consumers are in desperate need of effective treatment options, thus presenting an opportunity for companies in the healthcare industry to rise to the occasion.
Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) / (6PH.F), a Canadian publicly traded company focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry, is one such company that is pioneering new methods for how we go about providing treatment to patients. The Company has risen above others in the space because, at their core, they are forward-facing, consumer-focused, and truly wish to improve the quality of life for people suffering from harmful diseases.
In an industry wrought with inequity and challenged access, Premier has invested in strategic acquisitions to strengthen its offerings for its massive ecosystem of patients. In recognition of the vast potential of making medicinal cannabis more accessible to the healthcare industry, Premier has lead the way towards putting medicinal-grade cannabis in the hands of consumers.
Last week, the Company announced that, as part of its expansion plans, it is now formally entering the cannabis clinic space. The times are changing and consumers are advocating for their lawmakers to pass legislation in support of marijuana legalization. Research has shown us that cannabis functions as an incredible anti-inflammatory, as well as a resource for those struggling with anxiety, depression, eating disorders, and a plethora of other health challenges.
Dr. Essam Hamza, CEO of Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) / (6PH.F), commented, “there has been a critical gap between the patient’s need for medical cannabis and the doctor’s knowledge and comfort level in prescribing it. At Premier we understand the frustration felt from both the patient and the doctor and are integrating what we think is a revolutionary process. This new tool will allow us to provide a much-needed service to the 287 clinics and almost 3 million patients in our ecosystem.”
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
